Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020023548 - ANTICORPS CIBLANT UN COMPLEXE COMPRENANT HLA-I NON CLASSIQUE ET NÉOANTIGÈNE ET LEURS PROCÉDÉS D'UTILISATION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

WHAT IS CLAIMED IS:

1. A monoclonal antibody or an antigen-binding fragment thereof, comprising a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 7, or SEQ ID NO: 15.

2. The monoclonal antibody of claim 1, wherein the light chain variable domain (VL) comprises an amino acid sequence at least 90%, at least 95%, at least 99% or 100% identical to an amino acid sequence set forth as SEQ ID NO: 7, or SEQ ID NO: 15.

3. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 99%, or 100% identical to an amino acid sequence set forth as SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 37.

4. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 7 and a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 8.

5. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 15 and a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 16.

6. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof selectively binds to a complex comprising an HLA-E and a

neoantigen.

7. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof does not have a binding affinity to (i) the HLA-E alone; or (ii) the neoantigen alone.

8. The monoclonal antibody of claim 1, wherein the neoantigen comprises, consisting essentially of, or consisting of a sequence according to SEQ ID NO: 38 (VMAPRTLFL).

9. The monoclonal antibody of claim 1, wherein the complex comprises the HLA-E and VMAPRTLFL (SEQ ID NO: 38).

10. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof is a murine antibody, a chimeric antibody, a camelid antibody, a humanized antibody, or a human antibody.

11. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof is a TCR-like antibody.

12. The monoclonal antibody of claim 1, wherein the monoclonal antibody or antigen binding fragment thereof antibody further comprises a conjugated therapeutic moiety.

13. The monoclonal antibody of claim 1, wherein the selective binding of the antibody to the complex comprising the HLA-E and the neoantigen induces an immune response in a cell.

14. The monoclonal antibody of claim 13, wherein the cell is a cancer cell.

15. A monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 37.

16. The monoclonal antibody of claim 15, wherein the heavy chain variable domain (VH) comprises an amino acid sequence at least 90%, at least 95%, at least 99%, or 100% identical to an amino acid sequence set forth as SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 37.

17. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80%, at least 90%, at least 95%, at least 99%, or 100% identical to an amino acid sequence set forth as SEQ ID NO: 7, or SEQ ID NO: 15.

18. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 8 and a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 7.

19. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 16 and a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 15.

20. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof selectively binds to a complex comprising an HLA-E and a

neoantigen.

21. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof does not have a binding affinity to (i) the HLA-E alone; or (ii) the neoantigen alone.

22. The monoclonal antibody of claim 15, wherein the neoantigen comprises, consisting essentially of, or consisting of a sequence according to SEQ ID NO: 38 (VMAPRTLFL).

23. The monoclonal antibody of claim 15, wherein the complex comprises the HLA-E and VMAPRTLFL (SEQ ID NO: 38).

24. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof is a murine antibody, a chimeric antibody, a camelid antibody, a humanized antibody, or a human antibody.

25. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof is a TCR-like antibody.

26. The monoclonal antibody of claim 15, wherein the monoclonal antibody or antigen binding fragment thereof antibody further comprises a conjugated therapeutic moiety.

27. The monoclonal antibody of claim 15, wherein the selective binding of the antibody to the complex comprising the HLA-E and the neoantigen induces an immune response in a cell.

28. The monoclonal antibody of claim 27, wherein the cell is a cancer cell.

29. A monoclonal antibody or an antigen-binding fragment thereof, comprising a light chain complementarity determining region (CDR) having an amino acid sequence at least 80% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 1-3, or 9-11.

30. The monoclonal antibody of claim 29, wherein the light chain complementarity determining region (CDR) has an amino acid sequence at least 90%, at least 95%, at least 99%, or 100% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 1-3, or 9-11.

31. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain complementarity determining region (CDR) having an amino acid sequence at least 80%, at least 90%, at least 95%, at least 99%, or 100% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 4-6, 12-14, 17-19, 21-23, 25-27, 29-31, and 33-35.

32. The monoclonal antibody claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 1, or SEQ ID NO:

9, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 2, or SEQ ID NO: 10, a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 3, or SEQ ID NO: 11, a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 29, or SEQ ID NO:

33, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, or SEQ ID NO: 34, and a heavy chain

complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 31, or SEQ ID NO: 35.

33. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 1, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 2, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 3.

34. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 9, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 10, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 11.

35. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 4, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 5, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 6.

36. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 12, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 13, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 14.

37. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 7, or SEQ ID NO: 15.

38. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 37.

39. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 7 and a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 8.

40. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 15 and a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 16.

41. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof selectively binds to a complex comprising an HLA-E and a neoantigen.

42. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof does not have a binding affinity to (i) the HLA-E alone; or (ii) the neoantigen alone.

43. The monoclonal antibody of claim 29, wherein the neoantigen comprises, consisting essentially of, or consisting of a sequence according to SEQ ID NO: 38 (VMAPRTLFL).

44. The monoclonal antibody of claim 29, wherein the complex comprises the HLA-E and VMAPRTLFL (SEQ ID NO: 38).

45. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof is a murine antibody, a chimeric antibody, a camelid antibody, a humanized antibody, or a human antibody.

46. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof is a TCR-like antibody.

47. The monoclonal antibody of claim 29, wherein the monoclonal antibody or antigen binding fragment thereof antibody further comprises a conjugated therapeutic moiety.

48. The monoclonal antibody of claim 29, wherein the selective binding of the antibody to the complex comprising the HLA-E and the neoantigen induces an immune response in a cell.

49. The monoclonal antibody of claim 48, wherein the cell is a cancer cell.

50. A monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain complementarity determining region (CDR) having an amino acid sequence at least 80% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 4-6, 12-14, 17-19, 21-23, 25-27, 29-31, and 33-35.

51. The monoclonal antibody of claim 50, wherein the heavy chain complementarity determining region (CDR) has an amino acid sequence at least 90%, at least 95%, at least 99%, or 100% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 4-6, 12-14, 17-19, 21-23, 25-27, 29-31, and 33-35.

52. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment comprises a light chain complementarity determining region (CDR) having an amino acid sequence at least 80%, at least 90%, at least 95%, at least 99%, or 100% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 1-3, and 9-11.

53. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 29, or SEQ ID NO:

33, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, or SEQ ID NO: 34, a heavy chain

complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 31, or SEQ ID NO: 35, a light chain complementarity determining region

1 (CDR1) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 1, or

SEQ ID NO: 9, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 2, or SEQ ID NO: 10, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 3, or SEQ ID NO: 11.

54. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 4, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 5, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 6.

55. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 12, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 13, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 14.

56. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 17, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 18, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 19.

57. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 21, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 22, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 23.

58. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 25, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 26, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 27.

59. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 29, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 30, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 31.

60. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 34, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 35.

61. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 1, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 2, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 3.

62. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises at least one of a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 9, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 10, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 11.

63. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 37.

64. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 7, or SEQ ID NO: 15.

65. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 8 and a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 7.

66. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 16 and a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 15.

67. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof selectively binds to a complex comprising an HLA-E and a

neoantigen.

68. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof does not have a binding affinity to (i) the HLA-E alone; or (ii) the neoantigen alone.

69. The monoclonal antibody of claim 50, wherein the neoantigen comprises, consisting essentially of, or consisting of a sequence according to SEQ ID NO: 38 (VMAPRTLFL).

70. The monoclonal antibody of claim 50, wherein the complex comprises the HLA-E and VMAPRTLFL (SEQ ID NO: 38).

71. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof is a murine antibody, a chimeric antibody, a camelid antibody, a humanized antibody, or a human antibody.

72. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof is a TCR-like antibody.

73. The monoclonal antibody of claim 50, wherein the monoclonal antibody or antigen binding fragment thereof antibody further comprises a conjugated therapeutic moiety.

74. The monoclonal antibody of claim 50, wherein the selective binding of the antibody to the complex comprising the HLA-E and the neoantigen induces an immune response in a cell.

75. The monoclonal antibody of claim 74, wherein the cell is a cancer cell.

76. A pharmaceutical composition comprising: a monoclonal antibody or an antigen binding fragment thereof according to any one of claims 1 to 75; and a pharmaceutically acceptable carrier or excipient.

77. A method of treating cancer in an individual in need thereof, comprising

administering to the individual an effective amount of a monoclonal antibody or an antigen binding fragment thereof comprising a light chain complementarity determining region (CDR) having an amino acid sequence at least 80%, at least 90%, at least 95%, at least 99%, or 100% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 1-3, or 9-11.

78. The method of claim 77, wherein the monoclonal antibody or an antigen-binding fragment thereof comprises a heavy chain complementarity determining region (CDR) having an amino acid sequence at least 80%, at least 90%, at least 95%, at least 99%, or 100% identical to at least one of the amino acid sequences set forth as SEQ ID NOS: 4-6, 12-14, 17-19, 21-23, 25-27, 29-31, and 33-35.

79. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 1, or SEQ ID NO: 9, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 2, or SEQ ID NO: 10, a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 3, or SEQ ID NO: 11, a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 29, or SEQ ID NO:

33, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 30, or SEQ ID NO: 34, and a heavy chain

complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to one of SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 27, SEQ ID NO: 31, or SEQ ID NO: 35.

80. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 1, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 2, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 3.

81. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a light chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 9, a light chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 10, and a light chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 11.

82. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 4, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 5, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 6.

83. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 12, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 13, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 14.

84. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 17, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 18, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 19.

85. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 21, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 22, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 23.

86. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 25, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 26, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 27.

87. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 29, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 30, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 31.

88. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises at least one of a heavy chain complementarity determining region 1 (CDR1) having an amino acid sequence at least 80% identical to SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR2) having an amino acid sequence at least 80% identical to SEQ ID NO: 34, and a heavy chain complementarity determining region 3 (CDR3) having an amino acid sequence at least 80% identical to SEQ ID NO: 35.

89. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 7, or SEQ ID NO: 15.

90. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to an amino acid sequence set forth as SEQ ID NO: 8, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 36, or SEQ ID NO: 37.

91. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 7 and a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 8.

92. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable domain (VL) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 15 and a heavy chain variable domain (VH) comprising an amino acid sequence at least 80% identical to SEQ ID NO: 16.

93. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof selectively binds to a complex comprising an HLA-E and a neoantigen.

94. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof does not have a binding affinity to (i) the HLA-E alone; or (ii) the neoantigen alone.

95. The method of claim 77, wherein the neoantigen comprises, consisting essentially of, or consisting of a sequence according to SEQ ID NO: 38 (VMAPRTLFL).

96. The method of claim 77, wherein the complex comprises the HLA-E and

VMAPRTLFL (SEQ ID NO: 38).

97. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof is a murine antibody, a chimeric antibody, a camelid antibody, a humanized antibody, or a human antibody.

98. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof is a TCR-like antibody.

99. The method of claim 77, wherein the monoclonal antibody or antigen-binding fragment thereof antibody further comprises a conjugated therapeutic moiety.

100. The method of claim 77, wherein the selective binding of the antibody to the complex comprising the HLA-E and the neoantigen induces an immune response in a cell.

101. The method of claim 100, wherein the immune response comprises activation of

T cells.

102. The method of claim 101, wherein the T cell is a CD 8+ T cell.

103. The method of claim 100, wherein the immune response comprises activation of cytotoxic T cells (CTLs).

104. The method of claim 77, wherein the antibody is administered continuously, at predetermined time intervals, or intermittently for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, 15, 28, 30 or more days.

105. The method of claim 77, wherein the antibody is administered in 1 dose, 2 doses, 3 doses, 4 doses, 5 doses, 6 doses or more.

106. The method of claim 77, wherein the antibody is administered at a therapeutically effective amount.

107. The method of claim 77, wherein the cancer is breast cancer, kidney cancer, lung cancer, ovarian cancer, colorectal cancer, or a B-cell malignancy.